Literature DB >> 7016319

Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation.

M A Cornbleet, R E Corringham, H G Prentice, E M Boesen, T J McElwain.   

Abstract

Three patients with disseminated, relapsed Ewing's sarcoma refractory to conventional chemotherapy were treated with high-dose melphalan, cyclophosphamide pretreatment, and bone marrow autotransplantation. Two patients achieved complete remission and one achieved partial remission. The two patients who achieved complete remission remain disease-free at 12 and 13 months. High-dose melphalan is effective when conventional approaches have failed.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7016319

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  13 in total

1.  Hematopoietic reconstitution after high-dose chemotherapy and autologous nonfrozen bone marrow rescue.

Authors:  H Köppler; K H Pflüger; K Havemann
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

Review 2.  Autotransplants with peripheral blood stem cells and clinical results obtained in children: a review.

Authors:  K Leibundgut; A Hirt; A R Lüthy; A Tobler; H P Wagner
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

3.  The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.

Authors:  D Cunningham; J Cummings; R B Blackie; L McTaggart; S W Banham; S B Kaye; M Soukop
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

4.  High dose melphalan with autologous bone marrow transplantation in the treatment of metastatic Ewing's sarcoma.

Authors:  S R McCann; M Reynolds; R Meldrum; B Breslin; T Walsh; I J Temperley; P A Daly
Journal:  Ir J Med Sci       Date:  1983-04       Impact factor: 1.568

5.  High-dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus.

Authors:  R L Souhami; P G Harper; D Linch; C Trask; A H Goldstone; J S Tobias; S G Spiro; D M Geddes; J D Richards
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.

Authors:  M H Gaspard; D Maraninchi; A M Stoppa; J A Gastaut; G Michel; N Tubiana; D Blaise; G Novakovitch; J F Rossi; P J Weiller
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.

Authors:  J Ninane; R Baurain; A de Selys; A Trouet; G Cornu
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).

Authors:  A C Jones; P A Wilson; G G Steel
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 9.  Intensive chemotherapy for solid tumours--current clinical applications.

Authors:  S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Phase-I-II study of high-dose melphalan and autologous marrow transplantation in adult patients with poor-risk non-Hodgkin's lymphomas.

Authors:  B Mascret; D Maraninchi; J A Gastaut; D Baume; G Sebahoun; C Lejeune; G Novakovitch; D Sainty; N Horchowski; N Tubiana
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.